vedolizumab-话题@MedSci - 梅斯（MedSci）

#vedolizumab#

26篇内容 | 1724人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1455241, encodeId=67921455241d3, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=J Immunother Cancer：英夫利昔单抗((infliximab)和维多珠单抗(vedolizumab)) 治疗免疫介导的腹泻和结肠炎(IMDC)的疗效和安全性, objectType=article, longId=220663, objectId=82c1220663af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82c1220663af, replyNumber=0, likeNumber=70, createdTime=2021-11-22, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c1220663af, moduleTitle=J Immunother Cancer：英夫利昔单抗((infliximab)和维多珠单抗(vedolizumab)) 治疗免疫介导的腹泻和结肠炎(IMDC)的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=82c1220663af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455240, encodeId=6244145524086, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=ACG 2020：相比于英夫利昔单抗，Vedolizumab显著改善与免疫治疗有关的腹泻, objectType=article, longId=202652, objectId=2f2020265283, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f2020265283, replyNumber=0, likeNumber=0, createdTime=2020-10-31, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f2020265283, moduleTitle=ACG 2020：相比于英夫利昔单抗，Vedolizumab显著改善与免疫治疗有关的腹泻, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2f2020265283)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455239, encodeId=00301455239ea, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=Entyvio（Vedolizumab）长期维持治疗中重度活动性溃疡性结肠炎：安全性和有效性值得肯定, objectType=article, longId=202042, objectId=d5352020421a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5352020421a, replyNumber=0, likeNumber=85, createdTime=2020-10-14, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5352020421a, moduleTitle=Entyvio（Vedolizumab）长期维持治疗中重度活动性溃疡性结肠炎：安全性和有效性值得肯定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d5352020421a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455238, encodeId=526d1455238dd, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=Gastroenterology：Vedolizumab皮下注射在溃疡性结肠炎患者中的疗效和安全性, objectType=article, longId=188609, objectId=03481886094b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03481886094b, replyNumber=0, likeNumber=71, createdTime=2020-02-24, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03481886094b, moduleTitle=Gastroenterology：Vedolizumab皮下注射在溃疡性结肠炎患者中的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=03481886094b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455237, encodeId=d22b145523e34, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=J Gastroenterology ：vedolizumab在日本克罗恩病患者的疗效, objectType=article, longId=186482, objectId=7b7518648237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b7518648237, replyNumber=0, likeNumber=104, createdTime=2020-01-20, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b7518648237, moduleTitle=J Gastroenterology ：vedolizumab在日本克罗恩病患者的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7b7518648237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455236, encodeId=ce8c145523615, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=J Gastroen Hepatol：Vedolizumab主动代替抗TNF用于IBD患者的维持治疗, objectType=article, longId=186146, objectId=4bc41861462d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bc41861462d, replyNumber=0, likeNumber=84, createdTime=2020-01-14, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bc41861462d, moduleTitle=J Gastroen Hepatol：Vedolizumab主动代替抗TNF用于IBD患者的维持治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4bc41861462d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455235, encodeId=d85614552350d, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=NEJM：Vedolizumab vs 阿达木单抗治疗中重度溃疡性结肠炎, objectType=article, longId=180113, objectId=46ef18011370, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ef18011370, replyNumber=0, likeNumber=76, createdTime=2019-09-28, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ef18011370, moduleTitle=NEJM：Vedolizumab vs 阿达木单抗治疗中重度溃疡性结肠炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=46ef18011370)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455234, encodeId=30ed145523417, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=JCC：溃疡性结肠炎维持治疗期间Vedolizumab的谷浓度水平和组织学愈合相关, objectType=article, longId=178606, objectId=dfc01e860614, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfc01e860614, replyNumber=0, likeNumber=74, createdTime=2019-09-04, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfc01e860614, moduleTitle=JCC：溃疡性结肠炎维持治疗期间Vedolizumab的谷浓度水平和组织学愈合相关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dfc01e860614)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455233, encodeId=ddb91455233df, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=JCC：维持治疗期间较高的Vedolizumab谷浓度与炎症性肠病的无皮质类固醇缓解相关, objectType=article, longId=177925, objectId=ff281e792532, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff281e792532, replyNumber=0, likeNumber=85, createdTime=2019-08-20, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff281e792532, moduleTitle=JCC：维持治疗期间较高的Vedolizumab谷浓度与炎症性肠病的无皮质类固醇缓解相关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ff281e792532)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455232, encodeId=767a14552320f, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=Gastroenterology：300mgVedolizumab治疗中重度CD, objectType=article, longId=175617, objectId=cbc71e56176b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbc71e56176b, replyNumber=0, likeNumber=66, createdTime=2019-07-18, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbc71e56176b, moduleTitle=Gastroenterology：300mgVedolizumab治疗中重度CD, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cbc71e56176b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455231, encodeId=821f145523104, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=Gastroenterology Report： Vedolizumab可用于治疗抗生素难治性脓包皮炎, objectType=article, longId=174389, objectId=ecc81e4389e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecc81e4389e7, replyNumber=0, likeNumber=88, createdTime=2019-06-29, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecc81e4389e7, moduleTitle=Gastroenterology Report： Vedolizumab可用于治疗抗生素难治性脓包皮炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ecc81e4389e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455230, encodeId=38641455230ef, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=Dig Dis Sci：Vedolizumab浓度与炎症性肠病患者的长期内镜缓解相关, objectType=article, longId=168046, objectId=6407168046d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6407168046d7, replyNumber=0, likeNumber=75, createdTime=2019-06-12, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6407168046d7, moduleTitle=Dig Dis Sci：Vedolizumab浓度与炎症性肠病患者的长期内镜缓解相关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6407168046d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455229, encodeId=4bdf145522942, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=IBD：Vedolizumab诱导治疗中重度溃疡性结肠炎后粪便钙卫蛋白浓度变化, objectType=article, longId=162475, objectId=6a441624e551, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a441624e551, replyNumber=0, likeNumber=159, createdTime=2019-03-18, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a441624e551, moduleTitle=IBD：Vedolizumab诱导治疗中重度溃疡性结肠炎后粪便钙卫蛋白浓度变化, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6a441624e551)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455228, encodeId=269e14552280d, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=IBD：Vedolizumab血清水平与炎症性肠病的临床缓解，生物标志物正常化和粘膜愈合有关, objectType=article, longId=161709, objectId=4135161e09ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4135161e09ef, replyNumber=0, likeNumber=73, createdTime=2019-03-07, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4135161e09ef, moduleTitle=IBD：Vedolizumab血清水平与炎症性肠病的临床缓解，生物标志物正常化和粘膜愈合有关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4135161e09ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455227, encodeId=05d8145522efd, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=AP&T： Vedolizumab血清浓度与溃疡性结肠炎的临床结果之间的关系, objectType=article, longId=160228, objectId=693e1602281a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=693e1602281a, replyNumber=0, likeNumber=94, createdTime=2019-02-18, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=693e1602281a, moduleTitle=AP&T： Vedolizumab血清浓度与溃疡性结肠炎的临床结果之间的关系, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=693e1602281a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455226, encodeId=7a031455226a4, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=JCC： Vedolizumab可以在中度至重度活动性溃疡性结肠炎患者取得很好的深度缓解, objectType=article, longId=159692, objectId=46a415969265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46a415969265, replyNumber=0, likeNumber=65, createdTime=2019-02-11, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46a415969265, moduleTitle=JCC： Vedolizumab可以在中度至重度活动性溃疡性结肠炎患者取得很好的深度缓解, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=46a415969265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455225, encodeId=ce49145522523, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=Clin Gastroenterology H：监测炎症性肠病患者Vedolizumab谷浓度可以评估治疗预后, objectType=article, longId=155875, objectId=69b41558e512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69b41558e512, replyNumber=0, likeNumber=86, createdTime=2018-12-17, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69b41558e512, moduleTitle=Clin Gastroenterology H：监测炎症性肠病患者Vedolizumab谷浓度可以评估治疗预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=69b41558e512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455224, encodeId=b7da1455224a9, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=Gastroenterology ：Vedolizumab治疗活动期克罗恩病治疗响应的预测模型, objectType=article, longId=139475, objectId=1d4c1394e56a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d4c1394e56a, replyNumber=0, likeNumber=83, createdTime=2018-06-01, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d4c1394e56a, moduleTitle=Gastroenterology ：Vedolizumab治疗活动期克罗恩病治疗响应的预测模型, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1d4c1394e56a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455223, encodeId=bc4214552234d, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=Clin Gastroenterlogy and Hepatology： Vedolizumab浓度，抗药物抗体和α4β7基因与炎症性肠病患者反应的关系, objectType=article, longId=139401, objectId=508513940142, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=508513940142, replyNumber=0, likeNumber=62, createdTime=2018-05-31, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=508513940142, moduleTitle=Clin Gastroenterlogy and Hepatology： Vedolizumab浓度，抗药物抗体和α4β7基因与炎症性肠病患者反应的关系, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=508513940142)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455222, encodeId=267c145522284, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, objectTitle=GUT：Vedolizumab治疗炎症性肠病的作用机制, objectType=article, longId=137529, objectId=d31c13e529d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31c13e529d7, replyNumber=0, likeNumber=82, createdTime=2018-05-10, rootId=0, userName=yankaienglish, userId=f78f5645466, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31c13e529d7, moduleTitle=GUT：Vedolizumab治疗炎症性肠病的作用机制, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d31c13e529d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

vedolizumab

2020-05-29

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

J Immunother Cancer：英夫利昔单抗((infliximab)和维多珠单抗(vedolizumab)) 治疗免疫介导的腹泻和结肠炎(IMDC)的疗效和安全性

2021-11-22

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

ACG 2020：相比于英夫利昔单抗，Vedolizumab显著改善与免疫治疗有关的腹泻

2020-10-31

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

Entyvio（Vedolizumab）长期维持治疗中重度活动性溃疡性结肠炎：安全性和有效性值得肯定

2020-10-14

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

Gastroenterology：Vedolizumab皮下注射在溃疡性结肠炎患者中的疗效和安全性

2020-02-24

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

J Gastroenterology ：vedolizumab在日本克罗恩病患者的疗效

2020-01-20

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

J Gastroen Hepatol：Vedolizumab主动代替抗TNF用于IBD患者的维持治疗

2020-01-14

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

NEJM：Vedolizumab vs 阿达木单抗治疗中重度溃疡性结肠炎

2019-09-28

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

JCC：溃疡性结肠炎维持治疗期间Vedolizumab的谷浓度水平和组织学愈合相关

2019-09-04

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

JCC：维持治疗期间较高的Vedolizumab谷浓度与炎症性肠病的无皮质类固醇缓解相关

2019-08-20

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

Gastroenterology：300mgVedolizumab治疗中重度CD

2019-07-18

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

Gastroenterology Report： Vedolizumab可用于治疗抗生素难治性脓包皮炎

2019-06-29

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

Dig Dis Sci：Vedolizumab浓度与炎症性肠病患者的长期内镜缓解相关

2019-06-12

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

IBD：Vedolizumab诱导治疗中重度溃疡性结肠炎后粪便钙卫蛋白浓度变化

2019-03-18

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

IBD：Vedolizumab血清水平与炎症性肠病的临床缓解，生物标志物正常化和粘膜愈合有关

2019-03-07

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

AP&T： Vedolizumab血清浓度与溃疡性结肠炎的临床结果之间的关系

2019-02-18

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

JCC： Vedolizumab可以在中度至重度活动性溃疡性结肠炎患者取得很好的深度缓解

2019-02-11

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

Clin Gastroenterology H：监测炎症性肠病患者Vedolizumab谷浓度可以评估治疗预后

2018-12-17

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

Gastroenterology ：Vedolizumab治疗活动期克罗恩病治疗响应的预测模型

2018-06-01

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

Clin Gastroenterlogy and Hepatology： Vedolizumab浓度，抗药物抗体和α4β7基因与炎症性肠病患者反应的关系

2018-05-31

yankaienglish (审核中...)

前往app查看评论内容

#vedolizumab#

GUT：Vedolizumab治疗炎症性肠病的作用机制

2018-05-10

科室
- - 订阅+
  - 更多科室
工具
服务